GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

NNC0174-0833

Company
Novo Nordisk A/S
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT02300844

    Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male Subjects

    Not yet reported Novo Nordisk A/S 54 participants Est. completion 2016-03-21 1 site Stand-alone
    Other conditions: Metabolism and Nutrition Disorder, Obesity
    View official trial listing →
  • Completed NCT NCT02958085

    Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight

    Not yet reported Novo Nordisk A/S 96 participants Est. completion 2018-01-24 1 site Stand-alone
    Other conditions: Metabolism and Nutrition Disorder, Obesity
    View official trial listing →
  • Completed NCT NCT03600480

    A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese

    Not yet reported Novo Nordisk A/S 96 participants Est. completion 2020-06-12 1 site Added to GLP-1
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Completed NCT NCT03617081

    First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.

    Not yet reported Novo Nordisk A/S 40 participants Est. completion 2018-12-13 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03787225

    A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With Obesity

    Not yet reported Novo Nordisk A/S 66 participants Est. completion 2019-06-04 1 site Stand-alone
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Completed NCT NCT03856047

    Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.

    Not yet reported Novo Nordisk A/S 706 participants Est. completion 2021-03-25 54 sites Stand-alone
    Other conditions: Overweight, Obesity
    View official trial listing →
  • Completed NCT NCT04074174

    Research Study to Investigate the Effect of NNC0174-0833 on a Birth Control Pill in Women Who Are Not Able to Become Pregnant

    Not yet reported Novo Nordisk A/S 31 participants Est. completion 2020-03-06 1 site Stand-alone
    Other conditions: Overweight, Obesity
    View official trial listing →
  • Completed NCT NCT04209049

    A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney Function

    Not yet reported Novo Nordisk A/S 33 participants Est. completion 2021-01-05 2 sites Stand-alone
    Other conditions: Overweight, Obesity
    View official trial listing →
  • Completed NCT NCT04940078

    A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity

    Not yet reported Novo Nordisk A/S 40 participants Est. completion 2022-02-16 2 sites
    Other conditions: Obesity & Overweight
    View official trial listing →
  • Completed NCT NCT05016882

    Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

    Not yet reported Novo Nordisk A/S 698 participants Est. completion 2025-03-14 255 sites Added to GLP-1
    Other conditions: Non-alcoholic Steatohepatitis
    View official trial listing →
  • Completed NCT NCT05254158

    A Research Study of How NNC0174-0833 Behaves in Chinese Volunteers Who Are Normal Weight, Overweight or With Obesity

    Not yet reported Novo Nordisk A/S 24 participants Est. completion 2022-09-07 1 site Stand-alone
    Other conditions: Overweight and Obesity
    View official trial listing →
  • Completed NCT NCT05564104

    A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the Body

    Not yet reported Novo Nordisk A/S 32 participants Est. completion 2024-12-19 4 sites
    Other conditions: Hepatic Impairment, Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT05804162

    A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants

    Not yet reported Novo Nordisk A/S 107 participants Est. completion 2023-09-18 1 site
    Other conditions: Obesity
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.